A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer

Bryan R. Haugen, Furio Pacini, Christoph Reiners, Martin Schlumberger, Paul W. Ladenson, Steven I. Sherman, David S. Cooper, Kathryn E. Graham, Lewis E. Braverman, Monica C. Skarulis, Terry F. Davies, Leslie J. Degroot, Ernest L. Mazzaferri, Gilbert H. Daniels, Douglas S. Ross, Markus Luster, Mary H. Samuels, David V. Becker, Harry R. Maxon, Ralph R. CavalieriCarole A. Spencer, Kevin McEllin, Bruce D. Weintraub, E. Chester Ridgway

Research output: Contribution to journalArticlepeer-review

509 Scopus citations

Abstract

Recombinant human TSH has been developed to facilitate monitoring for thyroid carcinoma recurrence or persistence without the attendant morbidity of hypothyroidism seen after thyroid hormone withdrawal. The objectives of this study were to compare the effect of administered recombinant human TSH with thyroid hormone withdrawal on the resalts of radioiodine whole body scanning (WBS) and serum thyroglobalin (Tg) levels. Two hundred and twenty-nine adult patients with differentiated thyroid cancer requiring radioiodine WBS were studied. Radioiodine WBS and serum Tg measurements were performed after administration of recombinant human TSH and again after thyroid hormone withdrawal in each patient. Radioiodine whole body scans were concordant between the recombinant TSH-stimalated and thyroid hormone withdrawal phases in 195 of 220 (89%) patients. Of the discordant scans, 8 (4%) had superior scans after recombinant human TSH administration, and 17 (8%) had superior scans after thyroid hormone withdrawal (P = 0.108). Based on a serum Tg level of 2 ng/mL or more, thyroid tissue or cancer was detected during thyroid hormone therapy in 22%, after recombinant human TSH stimulation in 52%, and after thyroid hormone withdrawal in 56% of patients with disease or tissue limited to the thyroid bed and in 80%, 100%, and 100% of patients, respectively, with metastatic disease. A combination of radioiodine WBS and serum Tg after recombinant human TSH stimulation detected thyroid tissue or cancer in 93% of patients with disease or tissue limited to the thyroid bed and 100% of patients with metastatic disease. In conclusion, recombinant human TSH administration is a safe and effective means of stimulating radioiodine uptake and serum Tg levels in patients undergoing evaluation for thyroid cancer persistence and recurrence.

Original languageEnglish (US)
Pages (from-to)3877-3885
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume84
Issue number11
DOIs
StatePublished - 1999

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint

Dive into the research topics of 'A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer'. Together they form a unique fingerprint.

Cite this